The Effectiveness of Cannabinoids in the Management of Chronic Nonmalignant Neuropathic Pain: A Systematic Review
The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Abstract
AIMS: To carry out a systematic review to assess the effectiveness of cannabis extracts and cannabinoids in the management of chronic nonmalignant neuropathic pain. METHODS: Electronic database searches were performed using Medline, PubMed, Embase, all evidence-based medicine reviews, and Web of Science, through communication with the Canadian Consortium for the Investigation of Cannabinoids (CCIC), and by searching printed indices from 1950. Terms used were marijuana, marihuana, cannabis, cannabinoids, nabilone, delta- 9-tetrahydrocannabinol, cannabidiol, ajulemic acid, dronabinol, pain, chronic, disease, and neuropathic. Randomized placebo-controlled trials (RCTs) involving cannabis and cannabinoids for the treatment of chronic nonmalignant pain were selected. Outcomes considered were reduction in pain intensity and adverse events. RESULTS: Of the 24 studies that examined chronic neuropathic pain, 11 studies were excluded. The 13 included studies were rated using the Jadad Scale to measure bias in pain research. Evaluation of these studies suggested that cannabinoids may provide effective analgesia in chronic neuropathic pain conditions that are refractory to other treatments. CONCLUSION: Cannabis-based medicinal extracts used in different populations of chronic nonmalignant neuropathic pain patients may provide effective analgesia in conditions that are refractory to other treatments. Further high-quality studies are needed to assess the impact of the duration of the treatment as well as the best form of drug delivery.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Farrar, J. T., Young, J. P., LaMoreaux, L., Werth, J. L., & Poole, M. R. (2001) · Pain · doi:10.1016/s0304-3959(01)00349-9 · Cited by 5,808
Zajicek, J., Fox, P., Sanders, H., Wright, D., Vickery, J., Nunn, A., & Thompson, A. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14738-1 · Cited by 827 · cited 1×
“…measured for the entire sample Zajicek et al 28 Pain reduction was not the primary outcome for the study and was not measured for the entire sample Zajicek et al 29 Pain reduction was not the primary outcome for the study and was not measured for the entire sample Wissel et al 30 Pain was…”
ResultRandomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis
Rog, D. J., Nurmikko, T. J., Friede, T., & Young, C. A. (2005) · Neurology · doi:10.1212/01.wnl.0000176753.45410.8b · Cited by 679 · cited 7×
“But of note in this regard was the observation in one study 37 that the meta-analysis upon which Farrar et al 41 based the suggestion that a 30% reduction in pain was clinically significant “did not include patients with central neuropathic pain, in which relatively small decreases in pain…”
BackgroundResultInfluentialCannabinoids for control of chemotherapy induced nausea and vomiting: quantitative systematic review
Tramèr, M. R., Carroll, D., Campbell, F. A., Reynolds, D. J. M., Moore, R. A., & McQuay, H. J. (2001) · BMJ · doi:10.1136/bmj.323.7303.16 · Cited by 610 · cited 1×
“3,4 Historically, pain has been viewed as a symptom of more serious medical conditions, but more recently chronic pain has itself been regarded as a complex illness.”
BackgroundCannabis in painful HIV-associated sensory neuropathy: A randomized placebo-controlled trial
Abrams, D. I., Jay, C. A., Shade, S. B., Vizoso, H., Reda, H., Press, S., Kelly, M. E., Rowbotham, M. C., & Petersen, K. L. (2007) · Neurology · doi:10.1212/01.wnl.0000253187.66183.9c · Cited by 598 · cited 2×
“Abrams et al 35 reported smoked cannabis with 3.5% THC to be “well tolerated.””
BackgroundInfluentialWade, D. T., Makela, P., Robson, P., House, H., & Bateman, C. (2004) · Multiple Sclerosis Journal · doi:10.1191/1352458504ms1082oa · Cited by 589 · cited 3×
“17,18 Moreover, additional studies have been published since this systematic review, including one that utilized novel delivery methods 19 and two that used enriched enrollment to study only those patients deemed responsive to cannabinoid extracts.”
BackgroundSvendsen, K. B., Jensen, T. S., & Bach, F. W. (2004) · BMJ · doi:10.1136/bmj.38149.566979.ae · Cited by 500 · cited 2×
“In those studies that utilized synthetic cannabinoids, Karst et al 39 showed significant pain relief when CT-3 was compared with placebo, and Svendsen et al 38 showed clinically significant improvement in pain relief reflected in reductions in spontaneous median pain intensity and radiating pain.”
BackgroundSmoked Medicinal Cannabis for Neuropathic Pain in HIV: A Randomized, Crossover Clinical Trial
Ellis, R. J., Toperoff, W., Vaida, F., van den Brande, G., Gonzales, J., Gouaux, B., Bentley, H., & Atkinson, J. H. (2009) · Neuropsychopharmacology · doi:10.1038/npp.2008.120 · Cited by 461 · cited 2×
“Ellis et al 34 found a statistically significant decrease in pain as measured by the Descriptor Differential Scale in patients treated with cannabis compared with those treated with placebo.”
BackgroundMethodNurmikko, T. J., Serpell, M. G., Hoggart, B., Toomey, P. J., Morlion, B. J., & Haines, D. (2007) · Pain · doi:10.1016/j.pain.2007.08.028 · Cited by 431 · cited 6×
“Nurmikko et al 36 also showed a statistically significant reduction in mean pain intensity when comparing the same extract with placebo, with more patients in the active drug group reporting greater than 30% reduction.”
BackgroundResultInfluentialCannabinoids for treatment of chronic non‐cancer pain; a systematic review of randomized trials
Lynch, M. E., & Campbell, F. (2011) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2011.03970.x · Cited by 397 · cited 1×
“11 13 The most recent systematic review 15 included clinical trials of cannabinoids for chronic neuropathic pain, but also for chronic (non-cancer) pain related to fibromyalgia, rheumatoid arthritis, and mixed sources.”
BackgroundBerman, J. S., Symonds, C., & Birch, R. (2004) · Pain · doi:10.1016/j.pain.2004.09.013 · Cited by 362 · cited 7×
“,31–40 The cannabinoids administered for neuropathic pain therapy fall into three groups: whole plant, extract, and synthetic.”
BackgroundInfluentialKarst, M., Salim, K., Burstein, S., Conrad, I., Hoy, L., & Schneider, U. (2003) · JAMA · doi:10.1001/jama.290.13.1757 · Cited by 340
Cannabinoids in multiple sclerosis (CAMS) study: safety and efficacy data for 12 months follow up
Zajicek, J. P. (2005) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.2005.070136 · Cited by 335
A randomized, placebo-controlled, crossover trial of cannabis cigarettes in neuropathic pain
Wilsey, B., Marcotte, T., Tsodikov, A., Millman, J., Bentley, H., Gouaux, B., & Fishman, S. (2008) · The Journal of Pain · doi:10.1016/j.jpain.2007.12.010 · Cited by 327 · cited 5×
“Wilsey et al 19 found subjects who took either of the active drugs to be more sedated, confused, nau-seated, and hungry than those who took placebo.”
InfluentialCannabinoids as Pharmacotherapies for Neuropathic Pain: From the Bench to the Bedside
Rahn, E. J., & Hohmann, A. G. (2009) · Neurotherapeutics · doi:10.1016/j.nurt.2009.08.002 · Cited by 305
Langford, R. M., Mares, J., Novotna, A., Vachova, M., Novakova, I., Notcutt, W., & Ratcliffe, S. (2013) · Journal of Neurology · doi:10.1007/s00415-012-6739-4 · Cited by 298
Frank, B., Serpell, M. G., Hughes, J., Matthews, J. N. S., & Kapur, D. (2008) · BMJ · doi:10.1136/bmj.39429.619653.80 · Cited by 207 · cited 3×
“Furthermore, it included a trial solely comparing a cannabinoid with an active control group (dihydrocodeine) and no placebo control group 16 and two trials where pain was not the primary symptom targeted for each subject.”
BackgroundToth, C., Mawani, S., Brady, S., Chan, C., Liu, C., Mehina, E., Garven, A., Bestard, J., & Korngut, L. (2012) · Pain · doi:10.1016/j.pain.2012.06.024 · Cited by 174 · cited 2×
“20 Finally, in subjects who received the synthetic cannabinoid CT-3, tiredness and dry mouth were reported as the most frequent adverse effects, but no major physical adverse effects were observed.”
BackgroundWissel, J., Haydn, T., Müller, J., Brenneis, C., Berger, T., Poewe, W., & Schelosky, L. D. (2006) · Journal of Neurology · doi:10.1007/s00415-006-0218-8 · Cited by 171
Maurer, M., Henn, V., Dittrich, A., & Hofmann, A. (1990) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/bf02190083 · Cited by 117 · cited 1×
“24 Another was rejected because it consisted of 34 “n of 1” studies with patients who were not suffering exclusively from neuropathic pain.”
BackgroundCannabis for Chronic Pain: Case Series and Implications for Clinicians
Ware, M. A., Gamsa, A., Persson, J., & Fitzcharles, M.-A. (2002) · Pain Research and Management · doi:10.1155/2002/380509 · Cited by 38
Cited by
Cannabinoids for Medical Use: A Systematic Review and Meta-analysis
Whiting, P. F., Wolff, R. F., Deshpande, S., Di Nisio, M., Duffy, S., Hernandez, A. V., Keurentjes, J. C., Lang, S., Misso, K., Ryder, S., et al. (2015) · JAMA · doi:10.1001/jama.2015.6358 · Cited by 2,169
Cannabidiol: State of the art and new challenges for therapeutic applications
Pisanti, S., Malfitano, A. M., Ciaglia, E., Lamberti, A., Ranieri, R., Cuomo, G., Abate, M., Faggiana, G., Proto, M. C., Fiore, D., et al. (2017) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.02.041 · Cited by 614
Cannabis-based medicines for chronic neuropathic pain in adults
Mücke, M., Phillips, T., Radbruch, L., Petzke, F., & Häuser, W. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012182.pub2 · Cited by 571
Molecular Targets of the Phytocannabinoids: A Complex Picture
Morales, P., Hurst, D. P., & Reggio, P. H. (2017) · Progress in the Chemistry of Organic Natural Products · doi:10.1007/978-3-319-45541-9_4 · Cited by 454
Cannabinoids and Pain: New Insights From Old Molecules
Vučković, S., Srebro, D., Vujović, K. S., Vučetić, Č., & Prostran, M. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.01259 · Cited by 376
Metadata
- Authors
- Boychuk, D. G., Goddard, G., Mauro, G., & Orellana, M. F.
- Venue
- Journal of Oral & Facial Pain and Headache
- Publisher
- MRE Press
- Published
- 2015-01
- Volume
- 29
- Issue
- 1
- Pages
- 7-14
- ISSN
- 2333-0376 (ISSN-L)
- 2333-0384
- OpenAlex
- W2084188560
- Cited by
- 125
- References
- 21
- FWCI
- 10.36
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.